Quick Takeaways
- Capital World Investors filed SCHEDULE 13G/A for KalVista Pharmaceuticals, Inc. Common Stock (KALV).
- Disclosed ownership: 6.4%.
- Date of event: 31 Mar 2025.
Capital World Investors - 31 Mar 2025 SCHEDULE 13G/A Report for KalVista Pharmaceuticals, Inc. Common Stock (KALV)
- Filing Manager
- Capital World Investors
- Reporting Manager
- Capital World Investors
- Symbol
- KALV
- Shares outstanding
- 49,649,797 shares
- Disclosed Ownership
- 3,177,587 shares
- Ownership
- 6.4%
- Form type
- SCHEDULE 13G/A
- Filing time
- 13 May 2025, 11:44:14 UTC
- Date of event
- 31 Mar 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Capital World Investors disclosed 6.4% ownership in KalVista Pharmaceuticals, Inc. Common Stock (KALV) on 31 Mar 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 13 May 2025, 11:44.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Capital World Investors | 6.4% | 3,177,587 | 3,177,587 | 0 | Jae Won Chung | Vice President and Senior Counsel II, Capital Research and Management Company |